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The novel cardioprotective drug carvedilol was studied by both Raman spectroscopy and ab initio
molecular orbital methods (using the density functional theory approach). The spectra, acquired both
for the solid samples and DMSO solutions as a function of pH, were assigned in view of the calculated
wavenumbers and intensities, and also based on the experimental data obtained for individual compounds
which comprise the molecule, namely carbazole and 1,2-dimethoxybenzene. The pH dependence of the
Raman pattern of carvedilol was studied, and the pKa value of its secondary amine group was determined
(pKa = 8.25) through pH titration experiments. This kind of information is of great significance for the
understanding of the biochemical role of carvedilol, which is strongly determined by the acid–base
behaviour of the molecule. Copyright  2002 John Wiley & Sons, Ltd.
INTRODUCTION
Carvedilol (f1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyet-
hylamino] propanol-(2)g) is a compound displaying antiox-
idant properties, used in clinical practice for the treatment
of cardiovascular diseases (hypertension, congestive heart
failure or myocardial infarction).1,2 This drug was recently
proposed to act through protection of the mitochondrial
function,3 – 6 as cardiac dysfunctions are often correlated with
changes in mitochondrial bioenergetics. Carvedilol behaves
as a weak protonophore, carrying protons through the mito-
chondrial membrane, thus causing a lowering of the electric
membrane potential () created by ejection of HC by the
redox chain pumps.7 In this way, carvedilol may be proto-
nated in the cytoplasmic site, cross the membrane driven
by the inner negative electric field and then release its
amine proton into the matrix. This proposed cardioprotec-
tive effect is closely related to the acid–base characteristics of
the molecule, which emphasizes the importance of a correct
determination of its pKa value.
In a previous study,7 a conformational analysis of
carvedilol was carried out by ab initio self-consistent field
molecular orbital (SCF-MO) calculations for the different
protonation states of the molecule, and the corresponding
proton affinities were obtained. In the present work, a
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spectroscopic vibrational study of the molecule was carried
out and its pKa value was determined through analysis of
the changes in the band intensities upon protonation.
EXPERIMENTAL
Ab initioMO calculations
The ab initio SCF-MO calculations (total geometry opti-
mization as well as harmonic vibrational wavenumbers
and intensities) were performed using the Gaussian 98W
program,8 with the split valence basis set 3–21G.9 Molecular
geometries were fully optimized by the Berny algorithm,
using redundant internal coordinates:10 the bond lengths to
within ca 0.1 pm and the bond angles to within ca 0.1°. The
final root-mean-square (r.m.s.) gradients were always less
than 3 ð 104 hartree bohr1 or hartree rad1.
Raman spectroscopy
The Raman spectra were recorded on a Jobin-Yvon T64000
triple monochromator Raman system (0.640 m, f/7.5) with
holographic gratings of 1800 grooves mm1. The pre-
monochromator stage was used in the subtractive mode.
The detection system was a non-intensified CCD (charge-
coupled device). Radiation of 514.5 nm line from an argon
ion laser (Coherent Innova 300-05) was used for excitation,
providing ca 80 mW at the sample position, and a 90° geom-
etry was employed. The entrance slit was set to 200 µm and
the slit between the premonochromator and the spectrograph
was opened to 13.2 mm. An integration time of 5 s and 10–15
scans were used in all the experiments. Samples were sealed
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in Kimax glass capillary tubes of i.d. 0.8 mm. Under these
conditions, the error in wavenumbers was estimated to be
within 1 cm1.
FT-Raman spectra were obtained for the carbazole sam-
ple with a Bruker RFS 100/S spectrophotometer. Radiation of
1064 nm line from an Nd:YAG laser was used for excitation,
providing ca 100 mW at the sample position. The resolution
was set at 2 cm1 and a 180° geometry was employed.
Spectra were obtained for both solid samples (at 15 °C)
and 0.5 mol dm3 solutions (at 20 °C). Band intensity ratios
were evaluated by fitting Lorentzian bands to the experi-
mental spectra.
Sample preparation
Dimethyl-sulfoxide (DMSO) was used as a solvent for
carvedilol (0.5 mol dm3, owing to the low water solubility
of this compound. The pH of the solutions was adjusted
between 2.5 and 13.5 with HCl and CO2- free NaOH, using a
Sargent-Welch pH-meter coupled to a Radiometer PHC3006-
9 combined electrode.
Reagents
Carvedilol and carbazole (vetranal) were obtained from
Boehringer and Fluka/Riedel-de Hae¨n, respectively. DMSO
(HPLC grade), 1,2-dimethoxybenzene (veratrole, 99%), HCl
and NaOH (analytical grade) were purchased from Aldrich.
RESULTS AND DISCUSSION
Carvedilol was found to have two distinct conformers
in simultaneous equilibria in its unprotonated state, with
relative populations of 71% [(N)HÐÐÐO distance equal to
229 pm] and 29% [((N)HÐÐÐO distance equal to 239 pm],
and only one stable conformation in the protonated form
(displaying a significatively shorter (N)HÐÐÐO distance of
184 pm).7 Protonation of the molecule was found to
induce a severe change in the CcarbazolOCC dihedral angle,
from 79° (unprotonated compound) to 177° (protonated
species) (Fig. 1). In all cases, the molecule is stabilized
through intramolecular (O)HÐÐÐO and/or (N)HÐÐÐO hydrogen-
type interactions, which are determinant of its acid–base
characteristics and consequently of its biochemical effect
in living cells. Tables comprising the optimized geometric
parameters of carvedilol are available from the authors
upon request.
Figure 2(A) displays the Raman spectrum of solid
carvedilol, that was assigned based on its calculated
harmonic Raman wavenumbers and intensities (Table 1),
as well as on the comparison with the experimental spectra
obtained separately for two compounds which comprise
the molecule, 1,2-dimethoxybenzene and carbazole [Fig. 2(B)
and (C)]. Interestingly, these aromatic systems, situated at
two opposite ends of the carvedilol molecule, hardly interact
with each other, yielding rather localized vibrational modes,
which may actually be considered as group wavenumbers.
−79°
A
B
177°
Figure 1. Schematic representation of the lowest energy
conformations of carvedilol, in its unprotonated (A) and
N-protonated (B) forms.
In fact, the spectrum obtained for carvedilol can be viewed
as the result of a superposition of the individual spectra
of carbazole and 1,2-dimethoxybenzene (Fig. 2). A tentative
assignment of the Raman patterns corresponding to these
molecules is given in Table 1. Good agreement is found
between the present values and those recently reported for
carbazole by Lao et al.11
Figure 3 displays several Raman spectra of carvedilol
solutions in DMSO. Apart from the features due to the
solvent, the pattern observed is in close accord with the
results obtained for the solid sample (Fig. 2) and thus with
the assignments presented in Table 1.
The spectroscopic results obtained for these solutions,
at distinct pH values, undergo clear changes in the region
around 750 cm1 (Fig. 3), which reflect the presence of the
protonated and unprotonated forms of a secondary amine
group in the molecule (Fig. 1). The corresponding proto-
nation constant (pKa was therefore determined through
Raman pH titration experiments. Through analysis of the
spectra, it was verified that the protonation equilibrium can
be monitored through the band at ca 747 cm1, assigned to
the RNH2C group, as its intensity increases steadily on low-
ering the pH of the solution (Fig. 3). This feature may then be
used unequivocally as a measure of the concentration of the
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Figure 2. Raman spectra (175–1750, 2750–3500 cm1 of carvedilol (A), 1,2-dimethoxybenzene (B) and carbazole (C), in the
solid phase.
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Figure 3. Raman spectra (250–1750 cm1 of 0.5 mol dm3
solutions of carvedilol in DMSO, at 20 °C and distinct pH
values. The bands due to the solvent are marked with ♦.
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Figure 4. Molar fraction of the unprotonated and protonated
forms of carvedilol (DMSO solution, 0.5 mol dm3 as a
function of pH, and corresponding linear fit to the data. ž,
Unprotonated species;
°
, protonated species.
protonated form of the molecule. Upon obtaining spectra in
a broad region of pH (from 2.5 to 13.5), the molar fractions
of both the unprotonated and protonated species in solution
were calculated from the Raman intensity of that band, and
plotted as a function of pH (Fig. 4). Finally, the pKa was deter-
mined as being 8.25, from the pH value at the crossing points
of those curves. The band at ca 867 cm1, that remained
unchanged, both in wavenumber and intensity, throughout
the whole pH range studied, was used as an internal refer-
ence. Actually, the fact that this band, which was previously
ascribed to a mixed mode due to the indole NH bending
and ring deformation,13,14 is not affected by the variation in
pH is good evidence that protonation occurs only in one
of the nitrogen atoms of the carvedilol molecule (within its
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Table 1. Raman experimental wavenumbers (cm1) for carvedilol, 1,2-dimethoxibenzene (1,2-DMB) and carbazole, in the solid
state, with ab initio MO-calculated harmonic wavenumbers and intensities (IR, Raman) for carvedilol
Carvedilol 1,2-DMB Carbazole Approximate description
Experimental Calculateda
3346 3515 (80;92) OH stretching
3306 3501 (96;111) NH stretching (carbazole)
3261 3365 (14;39) NH stretching (chain)
3181 2 ð 1590
3074 3093 (0;205) 3079 CH sym. stretching (1,2-DMB)
3066 3089 (4;145) 3066 3057 CH sym. stretching (carbazole; 1,2-DMB)
3040 3061 (13;109) 3044 3038 sh CH antisym. stretching (carbazole; 1,2-DMB)
3013 3048 (1;53) 3015 CH antisym. stretching (carbazole)
2997 3010 (26;98) 3001 CH3 antisym. stretching
2968 2971 (15;50) 2962 CH stretching (chain); CH2 antisym. stretching (ethoxy)
2942 2949 (48;54) 2950 CH3 antisym. stretching
2926 2933 (19;35) CH2 (central) antisym. stretching
2907 2911 (22;71) 2911 CH2 sym. stretching
2879 2886 (47;85) CH2 sym. stretching
2849 2852 (46;56) CH2 (central) sym. stretching
2836 2902 (40;96) 2839 CH3 sym. stretching
1632 1626 (10;174) 1626 CC stretching (carbazole)
1591 1608 (57;44) 1590 CC stretching (1,2-DMB)
1574 1583 (8;31) 1573 CC stretching (carbazole)
1508 1530 (94,19) 1506 CC stretch. (1,2-DMB) C CH3 antisym. bend. C CH2 scissor.
1488 1500 (24;19) 1484 CC stretch., CH in-plane bend. (carbazole) C CH2 scissoring
1458 1483 (21;5) 1459 CC stretch., CH in-plane bend. (1,2-DMB) C CH3 sym. bend.
1445 1471 (30;2) 1445 CC stretch., CH in-plane bend. (1,2-DMB) C CH3 sym. bend.
1445 1454 (45;35) 1452 CC stretching, CH/NH in-plane bending (carbazole)
1348 1325 (30;13) CH2 wagging C CH2 twisting
1333 1315 (198;25) 1333 CC–OC sym. stretch., CH in-plane bending (1,2-DMB)
1333 1311 (6;11) 1337 CC stretching; CH in-plane bending (carbazole)
1299 (10;59) 1312 CN/CC sym. stretch.; CH in-plane bending (carbazole)
1285 1281 (3;17) 1292 CN sym. stretch., CC stretch., CH in-plane bending (carbazole)
1240 1248 (18;6) 1240 CC/CO stretch., CH in-plane bend. (carbazole) C CH2 twisting
1240 1241 (400;1) 1250 CC–OC antisym. stretching, ring antisym. bend. (1,2-DMB)
1223 1223 (24;20) 1226 CN antisym. stretching, NH in-plane bending (carbazole)
1216 1203 (31;81) 1207 CH in-plane bending (carbazole) C CC sym. stretching (pyrrole)
1182 (18;4) 1185/1179 CH3 rocking
1167 1169 (35;28) 1167 1160 CC stretching, CH in-plane bending (carbazole)
1145 1143 (1;7) 1149 CC stretching, CH in-plane bending (carbazole)
1124 1118 (54;16) 1108 CN antisym. stretch. (chain) C CC stretch., CH bend. (carbazole)
1064 1085 (62;8) CC/CN/C–OH stretching (chain) C CH2 rocking
1047 1053 (22;24) 1051 C–C/O–CH3 stretching, CH in-plane bending (1,2-DMB)
1022 (18;16) 1027 O–CH3 stretching (1,2-DMB)
1012 1005 (16;10) 1013 CC stretching (phenyl ring breathing, carbazole)
1000 981 (8;16) CH out-of-plane bending (carbazole) C CC/CN stretching (chain)
914 925 (27;8) 909 CCC/CNC deformation (carbazole) C CH2 rocking (linear chain)
865, 873 865 (8;13) 860/884 CCC/CNC deformation, NH in-plane bending (carbazole)
769 787 (111, 2) CH out-of-plane (‘butterfly’ of carbazole)
754 760 (33;24) NH perp. bend. (chain) C CCC in-plane bend. (1,2-DMB)
726 747 (96;9) 729/750 742 NH perp. bend. (chain) C CCC in-plane bend. (1,2-DMB, carbazole)
654 670 (1;4) 655 CCC/CNC in-plane deformation (carbazole)
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Table 1. (Continued)
Carvedilol 1,2-DMB Carbazole Approximate description
Experimental Calculateda
630 619 (7;3) CCC in-plane deformation (1,2-DMB)
576 571 (4;7) 581 COC deformation
549 557 (11;4) 552 Chain deformation C CCC deformation (carbazole)
538 539 (20;5) Chain deformation C CCC deformation (carbazole)
482 CCC deformation
462 453 (38;3) COH bending C chain deformation
426 420 (4;4) 431 Pyrrole ring breathing
402 394 (8;1) 383 COC/CCN/CCC chain deformation C COH bending
364 363 (3;4) Chain deformations
326 331 (0;7) 321 300 Phenyl–O–C deformations C out-of-plane phenyls bend. (carbazole)
310 280 (6;2) Chain deformations
276 272 (9;1) Chain deformations
245 234 (5;1) Chain torsions C chain deformations
222 Out-of-plane phenyls bending
206 O–CH3 torsion
191 200 (1;2) 193 Chain torsions
a For the most populated conformer, at the 3–21G level of calculation; scaled by a factor of 0.9085,12 for all wavenumbers above
400 cm1. IR intensities in km mol1; Raman scattering activities in A˚ u1.
linear chain), the carbazole group remaining unchanged. In
fact, the wavenumber of this Raman pattern is considered
by some workers14 as a probe of H-bonding occurring at the
nitrogen atom of the indole group.
The pKa value now obtained in DMSO solution is in
fairly good accord with that found in the literature for
carvedilol in phosphate saline medium: pKa D 7.9.15 Also,
the results from the present study agree completely with
those that we previously reported for the proton affinity of
carvedilol.7 In fact, having a weak affinity for protons (amine
pKa D 8.25) and carrying a positive charge at physiological
pH, this compound will be able easily to release HC within
the mitochondrial matrix, acting as an efficient cationic
protonophore, with relevance for a cardioprotection effect.7
CONCLUSIONS
The Raman spectra of carvedilol were obtained and assigned
for both the solid state and DMSO solution. Interpreta-
tion of the spectroscopic data was based on the calcu-
lated vibrational wavenumbers and intensities, obtained
through ab initio SCF-MO methods, and on the exper-
imental spectra for individual compounds which com-
prise the carvedilol molecule, namely 1,2-dimethoxybenzene
and carbazole.
The present work clearly evidences the utility of Raman
spectroscopy in the determination of pKa values in solu-
tion, provided that a clear pH dependence is detected
in the spectroscopic pattern during the protonation pro-
cess, and an unequivocal correlation between the bands
undergoing variation and a particular degree of proto-
nation of the molecule may be achieved. The pKa value
of the secondary amine group of carvedilol, in DMSO
solution, was now determined to be 8.25, in fairly good
accord with that previously reported using analytical
methods.15
Moreover, the fact that the experimental and calculated
Raman spectra found for carvedilol in the present work
display very good agreement reflects a close similarity
between the theoretical geometry and the real conformation
of the molecule. This may be of significance in future
studies aimed at the understanding of the structure–activity
relationships associated with the biological role of this
compound, already in clinical use.
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